WOODCLIFF LAKE, N.J., June 1, 2015 /PRNewswire/ — Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announces the immediate appointment of Ivor Macleod to the position of Senior Vice President, Chief Financial Officer (CFO) and Chief Compliance Officer. In this role, Mr. Macleod will have full oversight and responsibility for leading Eisai’s financial operations in the Americas Region, as well as head the compliance and internal audit functions. He will also serve on the company’s Executive Committee.
Mr. Macleod brings more than three decades of financial and operational expertise, which includes leading the financial teams at several major companies in the pharmaceutical sector within the United States and Europe. Most recently, he served as Vice President of Finance for the global research and development division of Merck & Co. Earlier in his career, Mr. Macleod spent 20 years with Hoffmann La Roche and Boehringer Mannheim Therapeutics, where he served in CFO roles within the United States and Germany as well as a member of the integration team that worked to bring the companies together via a merger in 1997. Mr. Macleod has been responsible for the billion dollar budgets of global research teams, formulating long-term strategic plans, managing stock portfolios, and supporting numerous business development activities, including acquisitions and mergers.
“Given Ivor’s vast experience and leadership positions at leading global companies within our industry, we are confident that Eisai is in excellent hands,” said Shaji Procida, President and Chief Operating Officer at Eisai Inc. “We are delighted to have him join the executive team at Eisai.”
Mr. Macleod holds a Master of Business Administration with a dual concentration in Accounting and Finance from the Eller College of Management at the University of Arizona. He earned a Bachelor of Science degree in Economics and Mathematics from the University of St. Andrews in Scotland. In addition, Mr. Macleod is a certified public accountant licensed in Virginia and a member of the American Institute of Certified Public Accountants. He also serves on the Board at the Essex County Family Justice Center in New Jersey.
At Eisai Inc., human health care is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to help address unmet medical needs. We are a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities. Our key areas of commercial focus include oncology and specialty care (Alzheimer’s disease, epilepsy and metabolic disorders). To learn more about Eisai Inc., please visit us at www.eisai.com/US.
Eisai Inc. has affiliates that are part of a global product creation organization that includes R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as a global demand chain organization that includes manufacturing facilities in Maryland and North Carolina. Eisai’s global areas of R&D focus include neuroscience; oncology; metabolic disorders; vascular, inflammatory and immunological reaction; and antibody-based programs.
Eisai Co., Ltd.
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as “giving first thought to patients and their families and to increasing the benefits health care provides,” which we call our human health care (hhc) philosophy. With over 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including oncology and neurology.
As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries. For more information about Eisai Co., Ltd., please visit www.eisai.com.
Source: PR Newswire Health